

- **Name:** Kyung-Hun Lee
 - **Current Position & Affiliation:** Professor
 - **Country:** Republic of Korea
-

• Educational Background:

- 1996-1998: Premedical Course, College of Natural Sciences, Seoul National University, Seoul, Korea
- 1998-2002: M.D., College of Medicine, Seoul National University, Seoul, Korea
- 2004-2007: M.S., College of Medicine, Seoul National University, Seoul, Korea
- 2007-2016: Ph.D., College of Medicine, Seoul National University, Seoul, Korea

• Professional Experience:

- 2002-03: Internship in Medicine, Seoul National University Hospital, Seoul, Korea
- 2003-07: Residency in Internal Medicine, Seoul National University Hospital, Seoul, Korea
- 2007-2010: Public Health Doctor, General Internist, National Forensic Psychiatric Hospital, Gongju-si, Korea
- 2010-2011: Clinical Fellow, Division of Hematology and Medical Oncology Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
- 2011-2016: Assistant Professor,
- 2016-2021: Associate Professor,
- 2021-current: Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
- 2019-2020: Visiting Assistant Researcher, University of California, San Francisco

s

• Professional Organizations:

- Korean Cancer Study Group
- Korean Cancer Association
- Korean Society of Medical Oncology
- American Society of Clinical Oncology
- American Association for Cancer Research
- European Society for Medical Oncology

• Main Scientific Publications:

1. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. *N Engl J Med.* 2018 Aug 23;379(8):753-763.
2. Lin CH, Yap YS, Lee KH, Im SA, Naito Y, Yeo W, Ueno T, Kwong A, Li H, Huang SH, Leung R, Han W, Tan B, Hu FC, Huang CS, Cheng AL, Lu YS, Asian Breast Cancer Cooperative

- Group. Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. *J Natl Cancer Inst.* 2019 Dec 1;111(12):1298-1306.
3. Min A, Jang H, Kim S, Lee KH, Kim DK, Suh KJ, Yang Y, Elvin P, O'Connor MJ, Im SA. Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response. *Mol Cancer Ther.* 2018 Dec;17(12):2507-2518.
 4. Lee DW, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH, Kim TY, Han SW, Oh DY, Im SA, Kim TY, Lee Y, Kim H, **Lee KH**. Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. *Clin Cancer Res.* 2021 Feb 1;27(3):713-718.
 5. Min A, Kim K, Jeong K, Choi S, Kim S, Suh KJ, **Lee KH**, Kim S, Im SA. Homologous repair deficiency score for identifying breast cancers with defective DNA damage response. *Sci Rep.* 2020 Jul 27;10(1):12506.
 6. Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, Hack SP, Spahn J, Liu B, Abdullah H, Wang Y, He AR, **Lee KH**; GO30140 investigators. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. *Lancet Oncol.* 2020 Jun;21(6):808-820.
 7. Suh KJ, Ryu HS, **Lee KH**, Kim H, Min A, Kim TY, Yang Y, Lee HB, Moon HG, Han SW, Oh DY, Han W, Park IA, Noh DY, Im SA. Prognostic effects of abnormal DNA damage response protein expression in breast cancer. *Breast Cancer Res Treat.* 2019 Jan 22. doi: 10.1007/s10549-019-05128-9.